Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changkang Granules for IBS-D (Liver qi affecting spleen)
NCT06753890Phase 3Not yet recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of changkang granules in irritable bowel syndrome (IBS), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
changkang granules
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06753890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06753890.